Literature DB >> 10991985

Antisense-mediated down-regulation of the human huntingtin gene.

R J Boado1, A Kazantsev, B L Apostol, L M Thompson, W M Pardridge.   

Abstract

The present study determines whether the expression of the huntingtin gene might be subject to antisense (AS)-mediated down-regulation. A series of AS oligodeoxynucleotides (ODNs) complementary to the huntingtin transcript [i.e., nucleotide (nt) -25 to 35] were designed and synthesized, and the AS efficacy was investigated by using a combination of in vitro transcription and translation to mimic in vivo conditions. An oligomer directed to nt -1 to 15 (ODN III) markedly reduced the incorporation of [(3)H]leucine into the huntingtin gene product in a dose-dependent manner (ED(50) of approximately 11.5 microM). ODNs that overlap with ODN III on both 5'- and 3'-flanking regions also produced translation arrest of the huntingtin protein; however, the AS-mediated effect of these ODNs represented approximately 50% of the effect of ODN III. In contrast, an ODN directed to nt 19 to 35 had no AS effect. The efficacy of ODN III also was investigated in an inducible, stably transfected PC-12 cell line expressing a truncated huntingtin exon 1 protein. In accordance with the cell free translation studies, ODN III (1-10 microM) markedly decreased the abundance of the huntingtin-green fluorescence fusion protein to 40 to 46% of the control levels. In summary, a series of putative AS candidates were screened for down-regulation of the huntingtin gene, and an ODN molecule directed to the methionine initiation codon was identified with maximum AS effects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10991985

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

Review 1.  Experimental surgical therapies for Huntington's disease.

Authors:  Jelle Demeestere; Wim Vandenberghe
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

2.  Allele-specific conditional destabilization of glutamine repeat mRNAs.

Authors:  Andrew B Crouse; Peter J Detloff
Journal:  Gene Expr       Date:  2005

3.  Replacement of huntingtin exon 1 by trans-splicing.

Authors:  Hansjörg Rindt; Pei-Fen Yen; Christina N Thebeau; Troy S Peterson; Gary A Weisman; Christian L Lorson
Journal:  Cell Mol Life Sci       Date:  2012-07-20       Impact factor: 9.261

Review 4.  Changes in laminin isoforms associated with brain tumor invasion and angiogenesis.

Authors:  Julia Y Ljubimova; Manabu Fujita; Natalya M Khazenzon; Alexander V Ljubimov; Keith L Black
Journal:  Front Biosci       Date:  2006-01-01

5.  Therapeutic Strategies in Huntington's Disease.

Authors:  Ichiro Kanazawa
Journal:  J Clin Neurol       Date:  2006-12-20       Impact factor: 3.077

6.  Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo.

Authors:  Eileen M Denovan-Wright; Edgardo Rodriguez-Lebron; Alfred S Lewin; Ronald J Mandel
Journal:  Neurobiol Dis       Date:  2007-11-12       Impact factor: 5.996

7.  Mouse Huntington's disease homolog mRNA levels: variation and allele effects.

Authors:  Karen T Dixon; Jamie A Cearley; Jesse M Hunter; Peter J Detloff
Journal:  Gene Expr       Date:  2004

8.  Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA.

Authors:  Jiaxin Hu; Masayuki Matsui; David R Corey
Journal:  Ann N Y Acad Sci       Date:  2009-09       Impact factor: 5.691

9.  Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid).

Authors:  Manabu Fujita; Bong-Seop Lee; Natalya M Khazenzon; Manuel L Penichet; Kolja A Wawrowsky; Rameshwar Patil; Hui Ding; Eggehard Holler; Keith L Black; Julia Y Ljubimova
Journal:  J Control Release       Date:  2007-06-05       Impact factor: 9.776

10.  Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs.

Authors:  Jiaxin Hu; Masayuki Matsui; Keith T Gagnon; Jacob C Schwartz; Sylvie Gabillet; Khalil Arar; Jun Wu; Ilya Bezprozvanny; David R Corey
Journal:  Nat Biotechnol       Date:  2009-05-03       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.